health pharma news today obesity drugs glp-1 today Drugmaker Eli Lilly announced that the FDA approved its daily pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports GLP-1 Market Expected to More

Quick Answer: GLP-1 receptor agonists improve fatty liver disease by reducing liver fat content, improving liver enzymes, and achieving NASH resolution in clinical trials, primarily through weight loss and enhanced insulin sensitivity

The group would be more than happy to answer any questions you might have and help you on your way to getting started

10.1038/s41573-020-00135-8 69 NevolaR.EpifaniR.ImbrianiS.TortorellaG.ApreaC.GalieroR.et al (2023)

BMC Public Health 24:1898 Xie Y, Choi T, Al-Aly Z (2025) Mapping the effectiveness and risks of GLP-1 receptor agonists

Others report a diminished sense of enjoyment from eating

[4] This study has been making the rounds on social media, leading many prominent influencers, both inside and outside the supplement world, to ask: is berberine nature's Ozempic